|Date||Title|| || |
|4/24/2017||New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria|
|Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) -- As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation.
Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed illumigene® Malaria, a molecular-based... || |
|4/17/2017||ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection|
|New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Leading malaria researcher Tom van Gool’s presentation at the 27th European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) will feature impressive results regarding a revolutionary breakthrough in the world of malaria detection. His presentation at ECCMID is scheduled for April 25, 2017, which is also World Malaria Day.
Dr. ... || |
|3/29/2017||Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal 2017 Operating Results on Thursday, April 27, 2017|
|CINCINNATI, March 29, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2017 operating results before the NASDAQ market opens on Thursday, April 27, 2017. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, mark... || |
|3/27/2017||Bioline Launches New JetSeq DNA Quantification Kits|
|CINCINNATI, March 27, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio for Next Generation Sequencing (NGS) sample preparation.
The new JetSeq™ Library Quantification Kit is a qPCR-based assay that provides fast, accurate and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina compatible NGS libraries. The JetSeq™ Libr... || |
|3/7/2017||Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs Exclusive Partnership to Provide Portable Blood Lead Testing in Africa|
|CINCINNATI, March 07, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian since March 2016, has signed an exclusive distribution agreement with Biofirm Technologies, one of the leading providers of laboratory equipment, consumables, reagents, and medical equipment in East and Central Africa. Magellan Diagnostics’ LeadCare® II blood lead testing system is the only FDA cleared, rapid and portable system capa... || |
|2/8/2017||Bioline Launches New JetSeq™ DNA Library Preparation Kits|
|CINCINNATI, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the JetSeq™ DNA Library Preparation portfolio for Next Generation Sequencing (NGS) sample preparation.
Developed in collaboration with Oxford Gene Technology (OGT), the new JetSeq™ DNA Library Preparation Kits use pre-optimized buffers to provide maximum reaction efficiency and highest conversion rates, enabling the pr... || |
|2/3/2017||Meridian Bioscience Announces the Launch of TruQuick™ Rapid Tests for Asia Pacific|
|CINCINNATI, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of TruQuick™, a comprehensive point-of-care product menu of rapid tests for the diagnosis of tropical, infectious, sexually transmitted, respiratory, gastrointestinal, cancer, and cardiac diseases. This product menu will enable Meridian to rapidly expand its product portfolio of high value rapid tests for its commercial operations in Asia Pacific and other emerging markets around th... || |
|1/25/2017||Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward|
CINCINNATI, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
reported first quarter net revenues of $46.8 million, a decrease of 1% from the same period of the prior fiscal year;
reported first quarter operating income of $10.1 million, a decrease of 26% from the same period of the prior fiscal year;
reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, decreases of 29% compared to the fiscal 20... || |
|1/12/2017||Microbix Appoints Meridian Life Science as Distributor in Asia Pacific|
|Meridian an Exclusive Distributor in China, Hong Kong, Taiwan and Macau TORONTO, ONTARIO--(Marketwired - Jan. 12, 2017) - Microbix Biosystems Inc. (TSX:MBX) ("Microbix"), an innovator of biological products and technologies, today announced it has signed a distribution agreement (the "Agreement") with Meridian Life Science, Inc. ("Meridian") a wholly owned company of Meridian Bioscience, Inc. (NASDAQ:VIVO) a fully integrated global diagnostic and life science company. Under the terms of the Ag... || |
|1/9/2017||Bioline Launches the Full Range of EPIK™ miRNA Assays|
|CINCINNATI, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the EPIK™ miRNA Select Assays, originally developed for the study of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March 2016 and this has now been increased to include all of the organisms listed on the miRBase release 21, which represents over 27,00... || |